Aprea Therapeutics (APRE) Cash from Financing Activities (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Cash from Financing Activities of $34.6 million for Q1 2026, up 61896.01% year-over-year from N/an in Q1 2025, and up 801.3% quarter-over-quarter from $3.8 million in Q4 2025.
Aprea Therapeutics (APRE) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Cash from Financing Activities for 9 consecutive years, with $34.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 61896.01% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $39.2 million (up 23233.0% YoY), while the FY2025 annual figure was $4.6 million, down 68.69% from the prior year.
- Cash from Financing Activities improved to $34.6 million in Q1 2026 per APRE's latest filing, from $3.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $34.6 million in Q1 2026 and bottomed at -$21060.0 in Q2 2024.
- Historically, Cash from Financing Activities has averaged $5.4 million across 5 years, with a median of $357940.0 in 2025.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities tumbled 99.62% — and 2026, when it soared 61896.01%.
- Aprea Therapeutics' Cash from Financing Activities stood at $98526.0 in 2022, then surged by 5116.89% to $5.1 million in 2023, then tumbled by 97.39% to $134405.0 in 2024, then jumped by 2758.2% to $3.8 million in 2025, then surged by 801.3% to $34.6 million in 2026.
- Business Quant data shows APRE's Cash from Financing Activities at $34.6 million in Q1 2026, $3.8 million in Q4 2025, and $357940.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | -1.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.94 Mn |
| Jun 30, 2026 | -1.94 Mn |
| Mar 31, 2026 | 34.62 Mn |
| Mar 31, 2026 | 34.62 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 357,940.00 |
| Sep 30, 2025 | 357,940.00 |
| Jun 30, 2025 | 384,879.00 |
| Jun 30, 2025 | 384,879.00 |
| Mar 31, 2025 | 55,849.00 |
| Mar 31, 2025 | 55,849.00 |
| Dec 31, 2024 | 134,405.00 |
| Dec 31, 2024 | 134,405.00 |
| Sep 30, 2024 | -1,155.00 |
| Sep 30, 2024 | -1,155.00 |
| Jun 30, 2024 | -21,060.00 |
| Jun 30, 2024 | -21,060.00 |
| Mar 31, 2024 | 14.71 Mn |
| Mar 31, 2024 | 14.71 Mn |